- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | RADIOPHARM THERANOSTICS LIMITED: Appendix 4E and Preliminary Final Report | - | ASX | ||
| Do | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Do | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notices x 4 | - | ASX | ||
| Mi | Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors | 175 | GlobeNewswire (Europe) | SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| Mi | RADIOPHARM THERANOSTICS LIMITED: RAD Doses First Patient in Second Cohort of BetaBart (RV-01) | - | ASX | ||
| Mo | RADIOPHARM THERANOSTICS LIMITED: Ceasing to be a substantial holder | 1 | ASX | ||
| 20.08. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.08. | Radiopharm advances RAD202 trial to higher dose level | 2 | Investing.com | ||
| 20.08. | Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial | 217 | GlobeNewswire (Europe) | Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated... ► Artikel lesen | |
| 20.08. | RADIOPHARM THERANOSTICS LIMITED: RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial | - | ASX | ||
| 17.08. | Radiopharm schedules FDA meeting for brain imaging agent RAD101 | 4 | Investing.com | ||
| 17.08. | Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases | 293 | GlobeNewswire (Europe) | RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 meeting with the U.S. FDA scheduled for October... ► Artikel lesen | |
| 17.08. | RADIOPHARM THERANOSTICS LIMITED: Change in substantial holding | 2 | ASX | ||
| 17.08. | RADIOPHARM THERANOSTICS LIMITED: RAD to meet with US FDA to align on RAD 101 Phase 3 Trial | 2 | ASX | ||
| 13.08. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.08. | RADIOPHARM THERANOSTICS LIMITED: Notice of Extraordinary General Meeting and Proxy Form | - | ASX | ||
| 07.08. | RADIOPHARM THERANOSTICS LIMITED: Share Purchase Plan - Now Open | 1 | ASX | ||
| 05.08. | RADIOPHARM THERANOSTICS LIMITED: Update - Proposed issue of securities - RAD | - | ASX | ||
| 03.08. | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | - | ASX | ||
| 31.07. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 3 4 5 Weiter >>
89 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,162 | +1,57 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Keine von der FDA zugelassene Exosomentherapie: Warum NurExone eine große Marktchance adressiert | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | +3,11 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,660 | +1,20 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,340 | 0,00 % | Onco-Innovations Limited: Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program | CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered... ► Artikel lesen | |
| NOVOCURE | 15,365 | -0,19 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,050 | +0,56 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 2,050 | +0,99 % | Oxford Nanopore Tech - Appointment of CDPO | ||
| ROCKET PHARMACEUTICALS | 3,400 | +2,10 % | ROCKET PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| PALISADE BIO | 2,000 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development | Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,858 | +0,14 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer | FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,552 | -1,69 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA | Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industriesDeep expertise spans... ► Artikel lesen | |
| PERSONALIS | 14,605 | -0,92 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? |
RADIOPHARM THERANOSTICS LIMITED ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,390 Euro und damit -0,83 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.